A

• Strategic Execution & Ignite Operating System: The 'Ignite' transformation is delivering compounding benefits, including strategic pricing that contributed ~200 basis points to the top line in Q3, surpassing full-year targets. Operational discipline has resulted in operating margin expansion of over 210 basis points year-over-year.
• End Market Momentum: Pharma grew 12%, significantly ahead of expectations, driven by GLP-1 momentum (>70% YoY growth) and improved biotech funding. China grew 9%, exceeding flat expectations due to strong pharma and food demand, despite minimal stimulus impact.
• Innovation & Product Launches: New product launches, including the 9500 ICP-MS and flagship GC systems, are tracking ahead of plan with order funnels exceeding $60 million. The Altura column family is seeing rapid adoption, with a 28% quarter-over-quarter increase in new accounts.
• Reshoring Dynamics: Early benefits from pharma reshoring are materializing, with orders secured from five of the top 10 global pharma companies. The company expects significant revenue contributions from this trend starting in fiscal 2027.
• Operational Agility: Manufacturing excellence initiatives, such as the AI-enabled supply chain control tower and distributed manufacturing model, have improved order-to-shipment conversion rates and customer delivery performance to a record 95% without adding headcount.

• Full-Year Revenue: Raised core growth expectation to 5.8%-6.0% (midpoint +65 bps vs. prior guide), implying full-year revenue of $7.49-$7.51 billion.
• Full-Year EPS: Increased non-GAAP EPS guidance to $6.18-$6.21 (including tariff refunds), or $6.12-$6.15 ex-refunds, representing ~10% growth at the midpoint.
• Operating Margin: Raised full-year operating margin expansion target to over 100 basis points ex-tariff refunds (or >130 bps including refunds).
• Fourth Quarter Revenue: Expects reported revenue of $1.98-$2.0 billion, implying core growth of roughly 5.2%-6.2%.
• Fourth Quarter EPS: Expects EPS of $1.71-$1.74, representing 8%-9% growth.
• Segment/Region Updates: Raised full-year growth expectations for CAM to high single-digits, AMG and LDG to mid-to-high single-digits, China to mid-single-digits, and Asia ex-China to double-digits.

Agilent reported total revenue of $1.88 billion, growing 7.3% on a core basis. The Life Sciences and Diagnostics Group (LDG) drove performance with 10% core growth, fueled by low double-digit LC revenue growth and nearly 30% growth in the Advanced Therapeutics Division (ATD). The Applied Markets Group (AMG) grew 7% on a core basis, led by high single-digit spectroscopy growth and double-digit vacuum performance. The Agilent CrossLab Group (ACG) grew north of 5% on a core basis, driven by strong consumables uptake.

• Macroeconomic & Geopolitical Volatility: Rising material costs and inflationary pressures continue to impact margins, though mitigated by Ignite efficiencies. Geopolitical disruptions affect specific regions like MEA (Middle East/Africa) and refine-side operations in C&E.
• CDMO Timing Risks: The Advanced Therapeutics Division faces a challenging year-over-year comparison in Q4 due to the timing of regulatory submissions, leading to expected flattish growth despite strong long-term fundamentals.
• Currency Headwinds: While favorable in Q3, currency is now expected to be a modest tailwind for the remainder of the year, impacting reported growth rates.
• Execution Lag in Reshoring: While early wins are evident, the full financial impact of pharma reshoring is expected to build gradually into fiscal 2027 and beyond, requiring sustained execution.

Q: Jack Meehan asked about the visibility and margin dynamics for the specialty CDMO business given its strong growth.

A: Management confirmed confidence in mid-teens long-term growth. Train C will ramp up over the next 6-8 quarters, with majority capacity already booked. Margins are expected to align with broader business at full capacity, with any near-term negative impacts from pre-revenue depreciation mitigated by Ignite efficiencies.

Q: Vijay Kumar requested quantification of pharma reshoring orders and their contribution to fiscal 2027.

A: Agilent estimates a $1 billion reshoring opportunity through 2030, aiming to win one-third. Orders from five top-10 pharma companies were secured in Q3. Revenue will begin flowing in fiscal 2027, supported by a large existing install base and strategic customer program engagement.

Q: Tycho Peterson inquired about the CDMO guidance miss and margin trajectory for next year.

A: The flattish Q4 CDMO outlook is due to timing of customer regulatory submissions, not lack of demand. For FY27, management expressed high confidence in maintaining momentum and margin expansion via Ignite, though no specific 2027 guidance was provided.

Q: Michael Riskin sought details on the drivers behind the strong China performance.

A: Growth was broad-based, driven by double-digit pharma growth (GLP-1, peptide testing, biotech investment), high-single-digit CAM growth (advanced materials, PFAS testing), and robust food testing volumes. Competitive wins in CXO and PFAS sectors highlighted portfolio strength.

Q: Dan Leonard asked if reshoring demand is incremental or substitutive.

A: Management stated that instrument and service revenue from reshoring is entirely incremental. Consumables may see some substitution, but the overall instrument and service business represents net new demand.